Oct 2 (Reuters) - Antisense Therapeutics Ltd (ANP) :
- Advised by FDA that full clinical hold for phase IIb clinical study of ATL1102 for multiple sclerosis has been lifted
- Co's application to conduct clinical trial of ATL1102 has been approved by Human Research Ethics Committee
Oct 2 (Reuters) - Antisense Therapeutics Ltd (ANP) : Advised by...
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $75.73M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 281394 | 8.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.7¢ | 119843 | 1 |
View Market Depth
| Last trade - 08.01am 19/06/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable